Related Experiment Video
Updated: Feb 4, 2026

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions
Published on: October 21, 2022
CircRNA-regulated programmed cell death networks in cardiomyocytes: Molecular crosstalk and therapeutic translation
Wenhua Jiang1,2, Yuetong Li3, Zhenxiong Liu2
1Department of Cardiovascular Medicine, First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Insights
Circular RNAs (circRNAs) regulate programmed cell death (PCD) in cardiovascular diseases (CVDs). This review highlights circRNAs as potential diagnostic and therapeutic targets for heart conditions.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Genetics
Background:
- Cardiovascular diseases (CVDs) are a leading global health issue.
- Programmed cell death (PCD) pathways are critical in myocardial injury.
- Circular RNAs (circRNAs) are emerging regulators of cardiomyocyte fate.
Purpose of the Study:
- To review the role of circRNAs in modulating PCD in CVDs.
- To explore circRNA-based diagnostics and therapeutics for CVDs.
- To discuss future clinical translation strategies for circRNA research.
Main Methods:
- Literature review synthesizing current research on circRNAs and PCD in CVDs.
- Analysis of circRNA mechanisms including molecular sponging, protein interactions, and epigenetic regulation.
- Evaluation of diagnostic and therapeutic applications of circRNAs.
Main Results:
- CircRNAs act as key regulators of multiple PCD pathways (ferroptosis, apoptosis, pyroptosis, autophagy, necroptosis) in the heart.
- CircRNA expression patterns can be used for CVD stratification with high accuracy.
- Protective circRNAs delivered via viral vectors show efficacy in preclinical models of myocardial infarction.
- CRISPR-based editing and nanoplatforms show promise for circRNA-based therapies.
Conclusions:
- CircRNA networks represent promising theranostic targets for CVDs.
- Context-dependent circRNA functions and pathway crosstalk require further investigation.
- Tissue-specific delivery remains a challenge for clinical translation of circRNA therapies.
Abstract:
Cardiovascular diseases (CVDs) represent the predominant global health burden, where dysregulated programmed cell death (PCD) mechanisms critically drive myocardial injury pathogenesis. Circular RNAs (circRNAs), characterized by covalently closed structures conferring high stability, function as pivotal regulators coordinating cardiomyocyte fate through integrated networks encompassing ferroptosis, apoptosis, pyroptosis, autophagy, and necroptosis. This review synthesizes advances in understanding circRNA-mediated PCD modulation via molecular sponging, protein interactions, and epigenetic regulation. Key insights establish context-dependent circRNA functionality and validate circRNA-based diagnostic panels for CVDs stratification with enhanced accuracy. Therapeutically, viral vector-delivered protective circRNAs demonstrate significant efficacy in ameliorating post-infarction apoptosis and improving cardiac function. We further evaluate emerging CRISPR-based editing technologies and nanoplatform delivery systems for clinical translation, positioning circRNA networks as promising theranostic targets while highlighting unresolved questions regarding pathway crosstalk and tissue-specific delivery.
Related Concept Videos
Translational Regulation
Negative Regulator Molecules
Protein Networks
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Improving Translational Accuracy

